150 related articles for article (PubMed ID: 38376003)
1. Schizandrin A induces non-small cell lung cancer apoptosis by suppressing the epidermal growth factor receptor activation.
Zhu L; Wang Y; Huang X; Liu X; Ye B; He Y; Yu H; Lv W; Wang L; Hu J
Cancer Med; 2024 Jan; 13(2):e6942. PubMed ID: 38376003
[TBL] [Abstract][Full Text] [Related]
2. Schizandrin A can inhibit non‑small cell lung cancer cell proliferation by inducing cell cycle arrest, apoptosis and autophagy.
Zhu L; Wang Y; Lv W; Wu X; Sheng H; He C; Hu J
Int J Mol Med; 2021 Dec; 48(6):. PubMed ID: 34643254
[TBL] [Abstract][Full Text] [Related]
3. Schizandrin A Alleviates LPS-Induced Injury in Human Keratinocyte Cell Hacat Through a MicroRNA-127-Dependent Regulation.
Li S; Xie R; Jiang C; Liu M
Cell Physiol Biochem; 2018; 49(6):2229-2239. PubMed ID: 30257250
[TBL] [Abstract][Full Text] [Related]
4. [Mechanism of n-butanol fraction of Wenxia Formula combining with gefitinib in treating non-small cell lung cancer based on network pharmacology and in vitro experiment].
Chen RJ; Bi QY; Shi JM; Zhong J; Han JT; Ji XM
Zhongguo Zhong Yao Za Zhi; 2024 Jan; 49(2):471-486. PubMed ID: 38403323
[TBL] [Abstract][Full Text] [Related]
5. Schizandrin A inhibits cellular phenotypes of breast cancer cells by repressing miR-155.
Yan H; Guo M
IUBMB Life; 2020 Aug; 72(8):1640-1648. PubMed ID: 32623835
[TBL] [Abstract][Full Text] [Related]
6. Schizandrin A inhibits proliferation, migration and invasion of thyroid cancer cell line TPC-1 by down regulation of microRNA-429.
Ding Q; Li X; Sun Y; Zhang X
Cancer Biomark; 2019; 24(4):497-508. PubMed ID: 30909188
[TBL] [Abstract][Full Text] [Related]
7. Schizandrin A exerts anti-tumor effects on A375 cells by down-regulating H19.
Bi Y; Fu Y; Wang S; Chen X; Cai X
Braz J Med Biol Res; 2019; 52(10):e8385. PubMed ID: 31618367
[TBL] [Abstract][Full Text] [Related]
8. Schizandrin A induces the apoptosis and suppresses the proliferation, invasion and migration of gastric cancer cells by activating endoplasmic reticulum stress.
Pu H; Qian Q; Wang F; Gong M; Ge X
Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34498719
[TBL] [Abstract][Full Text] [Related]
9. Bio-informatics and in Vitro Experiments Reveal the Mechanism of Schisandrin A Against MDA-MB-231 cells.
Chen L; Ren LQ; Liu Z; Liu X; Tu H; Huang XY
Bioengineered; 2021 Dec; 12(1):7678-7693. PubMed ID: 34550868
[TBL] [Abstract][Full Text] [Related]
10. MEG3 is restored by schisandrin A and represses tumor growth in choriocarcinoma cells.
Ji L; Ma L
J Biochem Mol Toxicol; 2020 Apr; 34(4):e22455. PubMed ID: 32057180
[TBL] [Abstract][Full Text] [Related]
11. Schizandrin A enhances the efficacy of gefitinib by suppressing IKKβ/NF-κB signaling in non-small cell lung cancer.
Xian H; Feng W; Zhang J
Eur J Pharmacol; 2019 Jul; 855():10-19. PubMed ID: 31028739
[TBL] [Abstract][Full Text] [Related]
12. A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma.
Han X; Liang L; He C; Ren Q; Su J; Cao L; Zheng J
BMC Complement Med Ther; 2023 Nov; 23(1):422. PubMed ID: 37990309
[TBL] [Abstract][Full Text] [Related]
13. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
[TBL] [Abstract][Full Text] [Related]
14. Schizandrol A protects against Aβ
Song L; Yao L; Zhang L; Piao Z; Lu Y
Naunyn Schmiedebergs Arch Pharmacol; 2020 Sep; 393(9):1739-1752. PubMed ID: 31900522
[TBL] [Abstract][Full Text] [Related]
15. Schisandrin A inhibits triple negative breast cancer cells by regulating Wnt/ER stress signaling pathway.
Xu X; Rajamanicham V; Xu S; Liu Z; Yan T; Liang G; Guo G; Zhou H; Wang Y
Biomed Pharmacother; 2019 Jul; 115():108922. PubMed ID: 31048190
[TBL] [Abstract][Full Text] [Related]
16. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
17. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
18. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
[TBL] [Abstract][Full Text] [Related]
19. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
[TBL] [Abstract][Full Text] [Related]
20. [Blaps rynchopetera affects proliferation, migration, and invasion of non-small cell lung cancer: a study based on network pharmacology and in vivo and in vitro experiments].
Li XY; Ma K; Yan JN; You FC; Ma L
Zhongguo Zhong Yao Za Zhi; 2023 Jul; 48(13):3576-3588. PubMed ID: 37474991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
